Clinical Research Directory

Inclusion Criteria: * Age ≥18 years. * Histologically confirmed diagnosis of non-small cell lung cancer (NSCLC) or locally advanced/metastatic unresectable melanoma. * Patient scheduled to initiate anti-PD-(L)1 therapy, either as monotherapy or in combination (other immune checkpoint inhibitors, chemotherapy, etc.). * Baseline tumor assessment performed within 28 days prior to enrollment (CT scan of thorax, abdomen, and pelvis) with at least one measurable lesion according to RECIST 1.1 criteria. * Life expectancy \>6 months. * Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 at enrollment. * Patient able to provide informed consent and comply with study procedures. * Patient covered by a social security system or equivalent. Exclusion Criteria: * Prior treatment with immunotherapy. * Presence of EGFR or ALK mutation (applicable only to the lung cohort). * Presence of another synchronous malignancy. * Diagnosis of uveal melanoma. * Treatment with systemic immunosuppressants, including within 28 days prior to enrollment, or corticosteroids \>10 mg/day, including within 14 days prior to enrollment. * Disease not measurable according to RECIST 1.1 criteria. * Positive serology for HIV, HBV, or HCV. * Pregnant or breastfeeding women. * Inability to comply with study follow-up and visits for geographic, social, or psychological reasons. * Individuals deprived of liberty or under legal guardianship (including curatorship).